Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > The Spirit Molecule (DMT)

<< Previous

Bullboard Posts

Next >>

Comment by nodaytraderon Jan 13, 2022 12:28pm

168 Views

Post# 34313178

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The Spirit Molecule (DMT)

Thank you. That chart raises the question of why is it that Algernon's market cap is low compared to its peers.
today's trading shows the price as coming down and a company called Integral Wealth Securities Seems to have led the way and is quite active in the lower bidders list
as they present themselves as providing investment advice to clients, I am puzzled at how this activity helps clients.

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?